UCB To Conduct First Anti-TNF Head-to-head Study Between Cimzia(R) (certolizumab Pegol) And Humira(R)* (adalimumab)
Links shared publicly online about this topic.
- 268total visits
UCB To Conduct First Anti-TNF Head-to-head Study Between Cimzia(R) (certolizumab Pegol) And Humira(R)* (adalimumab)
UCB today announced its plan to launch the first industry sponsored anti-TNF head-to-head study that will assess the effectiveness of Cimzia® (certolizumab pegol) and Humira® (adalimumab)
View full resource at medicalnewstoday.com
Tags: Crohn's Disease Medication, Rheumatoid Arthritis Medication, Humira, Cimzia, UCB
Most Recently Shared on May 25, 2011 at 9:05 am By:
UCB To Conduct First Anti-TNF Head-to-head Study Between Cimzia(R) (certolizumab Pegol) And Humira(R)* (adalimumab) http://mnt.to/3Wj8
Advertisement
